Elena Nikulina

Eyepoint Pharmaceuticals announces pivotal data readout for DURAVYU in wet AMD

Eyepoint Pharmaceuticals announces pivotal data readout for DURAVYU in wet AMD
Eyepoint unveils LUGANO trial results

Eyepoint Pharmaceuticals has announced topline results from its LUGANO trial, the first of two pivotal Phase 3 studies evaluating DURAVYU for the treatment of wet age-related macular degeneration (AMD).

The LUGANO trial is a key step in the companys late-stage development program and could lead to a new treatment option for patients if subsequent results are positive. Detailed results and further information are available via the companys official communication.

Eyepoint previously reported Phase 3 enrollment completion for DURAVYU in diabetic macular edema trials, with topline data expected in late 2027, according to a recent update. The company’s most recent financial results and corporate strategy were outlined in its Q2 2026 report. These developments reflect Eyepoint’s ongoing efforts to advance DURAVYU across multiple indications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.